Extracorporeal Circuit with Bio-Active Surface
Medtronic Blood Systems
FDA Clearance Information
The device was cleared by the FDA through the 510(k) pathway on May 31, 1989. It is manufactured by Medtronic Blood Systems and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Use as an extracorporeal blood circuit during procedures requiring cardiopulmonary bypass.
- Use for circulating blood outside the body while supporting extracorporeal cardiac and pulmonary function.
- Use with compatible extracorporeal circulation equipment according to the manufacturer's labeling.
Clinical Applications
- Cardiopulmonary bypass during open-heart surgery.
- Extracorporeal circulation during aortocoronary bypass grafting.
- Blood circulation through a cardiac surgery heart-lung machine.
- Support of extracorporeal cardiac and pulmonary circulation when used as part of a compatible labeled system.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The circuit must be selected for compatibility with the heart-lung machine, oxygenator, pumps, connectors and other extracorporeal components.
- Circuit configuration and tubing dimensions vary by patient size, flow requirements and the intended procedure; use the manufacturer's specifications for component selection.
- The circuit requires priming, de-airing and handling by trained cardiopulmonary bypass or extracorporeal-circulation personnel.
- This is a blood-contacting, single-use device; anticoagulation and monitoring are managed according to the operative protocol and the patient's condition.
- MRI safety depends on the complete circuit and any connected components. An extracorporeal circuit should not be taken into an MRI environment unless its labeling specifically permits it.
Frequently Asked Questions
What are the clinical indications for extracorporeal circuit with bio-active surface?
The device is indicated for use in cardiopulmonary bypass procedures and ECMO support in cases of cardiogenic shock.
What outcomes have been reported in clinical studies?
Studies report effects on C5a concentration, granulocyte and leukocyte counts, and free hemoglobin levels during extracorporeal circulation.
What complications have been reported?
Reported complications include increased free hemoglobin and elevated leukocyte counts, suggesting potential inflammatory responses.